Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Immunology and Infection / Blocage ciblé d'anticorps par un conjugaison…
JoVE Journal
Immunology and Infection

A subscription to JoVE is required to view this content.

JoVE Journal Immunology and Infection
Blocage ciblé d'anticorps par un conjugaison bifonctionnel de peptide antigénique et de mimétrie fc-III (DCAF)
Use of In Vivo Imaging to Screen for Morphogenesis Phenotypes in Candida albicans Mutant Strains During Active Infection in a Mammalian Host
Journal (Immunology and Infection)
Use of In Vivo Imaging to Screen for Morphogenesis Phenotypes in Candida albicans Mutant Strains During Active Infection in a Mammalian Host
An In Vivo Mouse Model to Measure Naïve CD4 T Cell Activation, Proliferation and Th1 Differentiation Induced by Bone Marrow-derived Dendritic Cells
Journal (Immunology and Infection)
An In Vivo Mouse Model to Measure Naïve CD4 T Cell Activation, Proliferation and Th1 Differentiation Induced by Bone Marrow-derived Dendritic Cells
 
Click here for the English version

Blocage ciblé d'anticorps par un conjugaison bifonctionnel de peptide antigénique et de mimétrie fc-III (DCAF)

Article DOI: 10.3791/60063-v • 09:39 min • September 17th, 2019
September 17th, 2019 •
*1,2, *3, 2, 2, 2, 3, 1,2
1Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 2Mass Spectrometry Core Facility, School of Life Sciences, Westlake University, 3MOE Key Laboratory of Bioinformatics, Center for Synthetic and Systems Biology, School of Life Sciences, Tsinghua University
* These authors contributed equally

Chapters

Summary
Automatic Translation

Please note that all translations are automatically generated.

Click here for the English version.

Le développement d'une conjugaison bifonctionnelle de peptide antigénique et de mimétique Fc-III (DCAF) est nouveau pour l'élimination des anticorps nocifs. Ici, nous décrivons un protocole détaillé pour la synthèse de la molécule DCAF1, qui peut bloquer sélectivement l'anticorps 4G2 pour éliminer l'effet d'amélioration dépendant des anticorps pendant l'infection de virus de dengue.

Tags

Rétraction Numéro 151 DCAF thérapie ciblée anticorps ligature chimique indigène synthèse de peptide de phase solide expression et purification de protéine ELISA
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter